Clinical Trials on Moderate to Severe Palmoplantar Psoriasis in Peru
Total 8 results
-
AbbVie (prior sponsor, Abbott)Terminated
-
Astellas Pharma IncBiogenCompleted
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-type PsoriasisBelgium, Spain, Russian Federation, Germany, United States, Czechia, Peru, Poland, Estonia
-
Hoffmann-La RochePfizerCompletedModerate to Severe Ulcerative ColitisUnited States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
-
AstraZenecaMedImmune LLCCompletedModerate to Very Severe Chronic Obstructive Pulmonary DiseaseUnited States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Janssen Vaccines & Prevention B.V.CompletedParticipants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the ProtocolUnited States, Mexico, South Africa, Brazil, Chile, Colombia, Peru, Argentina